

Datasheet for ABIN987824 Epiregulin Protein (EREG)



[Go to Product page](#)

Overview

Quantity:	1 mg
Target:	Epiregulin (EREG)
Origin:	Human
Source:	Escherichia coli (E. coli)
Biological Activity:	Active

Product Details

Sequence:	MVAQVSITKC SSDMNGYCLH GQCIYLVDMQ QNYCRCEVGY TGVRCEHFF
Characteristics:	Fully biologically active when compared to standard. The ED50 was determined by the dose-dependent stimulation of the proliferation of mouse Balb/3T3 cells is ≤ 2.0 ng/ml, corresponding to a specific activity of $\geq 5 \times 10^5$ units/mg.
Purity:	> 97 % by SDS-PAGE and HPLC analyses.
Endotoxin Level:	Level Less than 1EU/ μ g of rHuEREG as determined by LAL method

Target Details

Target:	Epiregulin (EREG)
Abstract:	EREG Products
Background:	Epiregulin is a member of the EGF family of growth factors which includes, among others, epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, amphiregulin (ARG), HB (heparin-binding)-EGF, betacellulin, and the various heregulins. It is expressed mainly in the placenta and peripheral blood leukocytes and in certain carcinomas of the bladder, lung, kidney

Target Details

and colon. Epiregulin stimulates the proliferation of keratinocytes, hepatocytes, fibroblasts and vascular smooth muscle cells. It also inhibits the growth of several tumor-derived epithelial cell lines. Human Epiregulin is initially synthesized as a glycosylated 19.0 kDa transmembrane precursor protein, which is processed by proteolytic cleavage to produce a 6.0 kDa mature secreted sequence. Synonym: Epiregulin (EREG), Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH7.4, 130mM NaCl.

Molecular Weight: Approximately 6.0 KDa, a single non-glycosylated polypeptide chain containing 50 amino acids.

Pathways: [RTK Signaling](#), [Fc-epsilon Receptor Signaling Pathway](#), [EGFR Signaling Pathway](#), [Neurotrophin Signaling Pathway](#), [Regulation of Muscle Cell Differentiation](#)

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.

Storage: 4 °C